C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/575 (2006.01)
Patent
CA 2677544
The use of opportunely modified specific ligands of the receptor for urotensin Il (UTR) or antibodies (commercially available) raised against the same receptor as tools for the definition of both the differentiation and the prognosis of human prostate adenocarcinoma is described, moreover, the use of opportunely radiolabeled ligands for UTR in the definition of the extension of disease is also described.
L'invention concerne l'utilisation de ligands spécifiques modifiés de façon opportune du récepteur pour l'urotensine II (UTR) ou d'anticorps (disponibles dans le commerce) dirigés contre le même récepteur en tant qu'outils pour la définition à la fois de la différenciation et le pronostic de l'adénocarcinome de la prostate masculine. De plus, l'invention concerne l'utilisation de ligands radiomarqués de façon opportune pour l'UTR dans la définition de l'extension de la maladie.
Addeo Santolo Rosario
Budillon Alfredo
Caraglia Michele
Franco Renato
Grieco Paolo
Addeo Santolo Rosario
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Budillon Alfredo
Caraglia Michele
Franco Renato
LandOfFree
Peptidic and non peptidic ligands for immunodetection of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptidic and non peptidic ligands for immunodetection of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidic and non peptidic ligands for immunodetection of the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1402944